Julie M. Fortier
A5035569976- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Immune Cell Function and Interaction
- Computational Drug Discovery Methods
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Monoclonal and Polyclonal Antibodies Research
- Acute Myeloid Leukemia Research
- Chemokine receptors and signaling
- Immunotherapy and Immune Responses
- HIV/AIDS drug development and treatment
- Malaria Research and Control
- Renal Diseases and Glomerulopathies
- Hematopoietic Stem Cell Transplantation
- Cancer-related molecular mechanisms research
- Cancer Genomics and Diagnostics
- CAR-T cell therapy research
- Hematological disorders and diagnostics
- Glycosylation and Glycoproteins Research
- Cancer Mechanisms and Therapy
- Medicinal Plant Pharmacodynamics Research
- Telomeres, Telomerase, and Senescence
- Zebrafish Biomedical Research Applications
- Lymphoma Diagnosis and Treatment
- Clinical Laboratory Practices and Quality Control
- Chronic Lymphocytic Leukemia Research
Washington University in St. Louis
2009-2025
Saint Louis University
2006
Université Laval
1991
Abstract Multiple myeloma (MM) is a highly refractory hematologic cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of identifying specific yet broadly representative tumor markers. We analyzed 53 bone marrow (BM) aspirates from 41 patients using an unbiased, high-throughput pipeline for therapeutic target discovery via single-cell transcriptomic profiling, yielding 38 marker genes encoding cell-surface proteins and 15 intracellular proteins. Of...
Abstract Natural killer (NK) cells are a promising approach for cellular cancer immunotherapy and being investigated to treat patients with multiple myeloma (MM). We found that MM patient blood NK cell frequencies were normal increased activating receptors cytotoxic granules, without evidence of functional exhaustion. Despite this activated state, target resistant conventional by unclear mechanisms. Memory-like (ML) generated after brief activation via the interleukin (IL)-12, IL-15, IL-18...
Abstract Hematologic malignancies, such as multiple myeloma, exhibit a markedly increased incidence with age and are profoundly influenced by the bone marrow microenvironment. The aged microenvironment can lead to accumulation of senescent cells, characterized permanent cell cycle arrest pro-inflammatory secretory phenotype. Despite its significance in age-related diseases, role cells their impact on aging hematologic malignancies remain poorly understood.As part Cellular Senescence Network...
Abstract Introduction: Landmark cancer genome sequencing programs have significantly advanced research, leading to novel therapies and preventive strategies. However, the underrepresentation of racial minority groups in these studies limits applicability findings leaves critical gaps understanding disparities. The Participant Engagement Cancer Genome Sequencing (PE-CGS) Network, established under National Institute’s Moonshot, seeks address by engaging with understudied populations. Multiple...
Abstract NK lytic-associated molecule (NKLAM) is a protein involved in the cytolytic function of cells and CTLs. It has been localized to granules up-regulated when are exposed cytokines IL-2 or IFN-β. We report this study that NKLAM contains cysteine-rich really interesting new gene (RING) between RING-RING domain, domain possesses strong homology RING known E3 ubiquitin ligase, Dorfin. To determine whether functions as an we performed coimmunoprecipitation binding assays with conjugates...
Abstract Background Serum free light chain (sFLC) assays are interpreted using a sFLC-ratio-based reference interval (manufacturer’s interval) that was defined cohort of healthy patients. However, renal impairment elevates the sFLC-ratio, leading to high false positive rate when manufacturer’s interval. Prior studies have developed renal-specific intervals; however, this approach has not been widely adopted due practical limitations. Thus, there remains critical need for renally robust sFLC...
Abstract Multiple myeloma (MM) is a cancer of bone marrow plasma cells (BMPCs), which to date remains incurable. Standard care for qualifying patients involves high-dose chemotherapy followed by autologous stem cell transplant (ASCT), after minimal residual disease (MRD) testing used assess the degree tumor clearance. Though strongly associated with better survival, MRD-negativity an imperfect predictor patient outcomes and fails account pro-tumorigenic BM dysregulation often found in MM...
<p>Pearson R correlation values between bulk RNA expression and scRNA in PCs for target genes.</p>
<p>supplementary figures</p>
<p>supplementary figures</p>
<p>NetMHC analysis output for tissue-specific intracellular genes. Only peptides identified as strong binders (% rank <0.5) are shown. Detailed explanation of each column can be found here: http://www.cbs.dtu.dk/services/NetMHC/output.php.</p>
<p>NetMHC analysis output for tissue-specific intracellular genes. Only peptides identified as strong binders (% rank <0.5) are shown. Detailed explanation of each column can be found here: http://www.cbs.dtu.dk/services/NetMHC/output.php.</p>
<p>List of recurrent mutations with potential utility as neoantigens</p>
<p>List of recurrent mutations with potential utility as neoantigens</p>
<p>Pearson R correlation values between bulk RNA expression and scRNA in PCs for target genes.</p>
<p>Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.</p>
<p>Batch specific co-expression analysis.</p>
<p>Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU 1.</p>
<p>Clinical information of patients in scRNA-seq discovery cohort, flow cytometry validation cohort and proteomics including age, gender, race, ISS stage, time to disease progression (TTPD). Disease stage for WashU 1.</p>
<p>Novelty description of candidate tumor markers. Each gene is ranked according to existing literature and/or clinical trials investigating its role in multiple myeloma. Representative studies are listed.</p>
<div>Abstract<p>Multiple myeloma (MM) is a highly refractory hematological cancer. Targeted immunotherapy has shown promise in MM but remains hindered by the challenge of identifying specific yet broadly representative tumor markers. We analyzed 53 bone marrow (BM) aspirates from 41 patients using an unbiased, high-throughput pipeline for therapeutic target discovery via single cell transcriptomic profiling, yielding 38 marker genes encoding cell-surface proteins and 15...